Richard M. Soll
Corporate Officer/Principal bei WUXI APPTEC CO., LTD.
Profil
Richard M.
Soll is currently the Director at the Children's Tumor Foundation and the SVP-International Discovery Service Unit at WuXi AppTec Co., Ltd.
He previously served as the Director & Manager at Simcha Therapeutics Holding Co. LLC, Vice President-Chemistry at 3-Dimensional Pharmaceuticals, Inc., CSO and Vice President-Research & Development at TargeGen, Inc., and Vice President-Chemistry at Ontogen Corp.
Dr. Soll holds a doctorate degree from Dartmouth College and an undergraduate degree from the University of Massachusetts.
Aktive Positionen von Richard M. Soll
| Unternehmen | Position | Beginn |
|---|---|---|
| WUXI APPTEC CO., LTD. | Corporate Officer/Principal | - |
| Children's Tumor Foundation | Director/Board Member | - |
Ehemalige bekannte Positionen von Richard M. Soll
| Unternehmen | Position | Ende |
|---|---|---|
TargeGen, Inc.
 TargeGen, Inc. Pharmaceuticals: MajorHealth Technology TargeGen, Inc. manufactures vascular biopharmaceutical products. The company was founded by David A. Cheresh and Peter G. Ulrich in 2001 and is headquartered in San Diego, CA. | Chief Tech/Sci/R&D Officer | 01.03.2008 |
| Ontogen Corp. | Corporate Officer/Principal | 01.03.2003 |
3-Dimensional Pharmaceuticals, Inc.
 3-Dimensional Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology 3-Dimensional Pharmaceuticals, Inc. was acquired by Johnson & Johnson. 3-Dimensional Pharmaceuticals, Inc. operates as a drug discovery and development company that has a pipeline of drug candidates in the areas of cancer and inflammation, and metabolic and cardiovascular diseases | Corporate Officer/Principal | 01.03.2002 |
Simcha Therapeutics Holding Co. LLC
 Simcha Therapeutics Holding Co. LLC BiotechnologyHealth Technology Simcha Therapeutics Holding Co. LLC is a biopharmaceutical company which engages in developing an engineered interleukin therapy. The company was founded in 2018 and is headquartered in New Haven, CT. | Director/Board Member | - |
Ausbildung von Richard M. Soll
| Dartmouth College | Doctorate Degree |
| University of Massachusetts | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| WUXI APPTEC CO., LTD. | Health Technology |
| Private Unternehmen | 5 |
|---|---|
3-Dimensional Pharmaceuticals, Inc.
3-Dimensional Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology 3-Dimensional Pharmaceuticals, Inc. was acquired by Johnson & Johnson. 3-Dimensional Pharmaceuticals, Inc. operates as a drug discovery and development company that has a pipeline of drug candidates in the areas of cancer and inflammation, and metabolic and cardiovascular diseases | Health Technology |
TargeGen, Inc.
TargeGen, Inc. Pharmaceuticals: MajorHealth Technology TargeGen, Inc. manufactures vascular biopharmaceutical products. The company was founded by David A. Cheresh and Peter G. Ulrich in 2001 and is headquartered in San Diego, CA. | Health Technology |
| Children's Tumor Foundation | Miscellaneous |
| Ontogen Corp. | |
Simcha Therapeutics Holding Co. LLC
Simcha Therapeutics Holding Co. LLC BiotechnologyHealth Technology Simcha Therapeutics Holding Co. LLC is a biopharmaceutical company which engages in developing an engineered interleukin therapy. The company was founded in 2018 and is headquartered in New Haven, CT. | Health Technology |
